Evidence map›Paper›PMID 41287180›Full record

Trial reportAddiction (Abingdon, England)2026

Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial.

Katharine A Bradley, Noorie Hyun, Abisola Idu, Onchee Yu, Jennifer F Bobb, Paige D Wartko, Zoe Weinstein, Abigail G Matthews, Jennifer McCormack, Amy K Lee and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Katharine A BradleyKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.ORCID https://orcid.org/0000-0003-1933-4425
Noorie HyunKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Abisola IduKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Onchee YuKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Jennifer F BobbKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Paige D WartkoKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Zoe WeinsteinBoston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Abigail G MatthewsThe Emmes Company, Rockville, MD, USA.
Jennifer McCormackThe Emmes Company, Rockville, MD, USA.
Amy K LeeKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Jeffrey H SametBoston Medical Center, Boston University Schools of Medicine and Public Health, Boston, MA, USA.
PROUD Trial collaborators on sex, race and ethnicity

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
CLC NIH HHS 75N90019D00013Data and Statistics Center, The Emmes Company 75N95019D00013Intramural Research Program UG1DA04031National Institute on Drug Abuse of the National Institutes of Health UG1DA040314NIDA NIH HHS 75N95021D00013NIDA NIH HHS HHSN271201400028CNIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA020024NIDA NIH HHS UG1 DA040314ORFDO NIH HHS 75N99019D00013U.S. Department of Health and Human Services
6 · The paper itself

Abstract

BACKGROUND AND

aimsFemale, Hispanic, and Black patients with opioid use disorder (OUD) are less likely to receive OUD medication treatment than other patients. The PROUD (PRimary care Opioid Use Disorders treatment) trial demonstrated that implementation of primary care (PC) nurse care management increases OUD medication treatment compared with usual care (UC). This study assessed whether the PROUD intervention's effect differed across sex, race and ethnicity.

designSecondary analyses of cluster-randomized implementation trial.

setting12 PC clinics (2 per health system) in five states in the USA, randomized to UC or intervention, stratified by health system.

participantsPC patients 16-90 years old.

interventionThree strategies to implement office-based addiction treatment (OBAT) by nurse care managers: (1) full-time nurse salary; (2) nurse training and technical assistance from expert nurses at Boston Medical Center; (3) ≥3 PC providers willing to prescribe buprenorphine. Nurses were trained in the Massachusetts model of OBAT which includes lowering barriers to OUD treatment, assessing and educating patients, supporting initiation of medications for OUD and providing ongoing medical management, in collaboration with PC providers. MEASUREMENTS: The primary outcome was a clinic-level measure of OUD treatment defined as patient-years of OUD treatment per 10 000 PC patients based on orders and procedures for buprenorphine or extended-release naltrexone from electronic health records and insurance claims (hereafter 'OUD treatment').

findingsThe mean numbers of patients seen by intervention and UC clinics at baseline were 18 485 and 22 557, respectively. Female patients comprised 60% of the total PC population in intervention clinics and 64% in UC clinics; Asian, Black, Hispanic or smaller racial groups comprised 61% of the PC population in intervention clinics, and 70% in UC clinics. Compared with UC, the intervention increased OUD treatment for male patients [adjusted difference: 13.7 patient-years; 95% confidence interval (CI) = 5.8-21.7], but not female patients (2.9; 95% CI = -4.3 to 10.2); effect modification test, F (1,14) = 4.77; P = 0.046. Exploratory analyses suggest that differences in the intervention's effect on receipt of any OUD treatment in female and male patients, rather than differences in the duration of OUD treatment, may account for findings. There was no significant effect modification by race or ethnic group [effect modification test F (4,44) = 1.50; P = 0.218].

conclusionsPrimary care clinics that implement office-based addiction treatment by nurses increase patient-years of opioid use disorder (OUD) treatment in male but not female patients. Exploratory findings suggest that differences in the proportion of patients treated for OUD, rather than differences in the duration of OUD treatment, account for observed differences across groups.

Indexed as

BuprenorphineOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareAdolescentAdultAgedAged, 80 and overFemaleHispanic or LatinoHumansMaleMiddle AgedNarcotic AntagonistsSex FactorsUnited StatesBuprenorphineNarcotic Antagonistsbuprenorphinecollaborative carenaltrexonenurse care manageropioid use disorderprimary careracesex

Identifiers

PMID41287180
PMCPMC12829311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.